Home | Business News | Browse by Publication | P | Pharma Marketletter

FDA OKs Evolutec's hay fever trial.

Publication: Pharma Marketletter
Publication Date: 25-APR-05
Format: Online
Delivery: Immediate Online Access
Full Article Title: FDA OKs Evolutec's hay fever trial.(pharmaceutical industry)(Brief Article)

Article Excerpt
UK biopharmaceutical group Evolutec, which is focused on the development of novel products for the treatment of allergic, inflammatory and autoimmune diseases, says it has obtained an Investigational New Drug approval from the US Food and Drug Administration to conduct a proof-of-concept study of its allergic rhinitis candidate rEV131....

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
FDA OKs Sinclair's Decapinol.(pharmaceutical industry)(Food and Drug A..., April 25, 2005
Andrx' metformin ER wins US FDA approval.(pharmaceutical industry)(Foo..., April 25, 2005
Spectrum begins trial of BPH drug.(pharmaceutical industry)(benign pro..., April 25, 2005
Acusphere expands AI-700 Ph III study population.(pharmaceutical indus..., April 25, 2005
Tysabri shows strong results as add-on MS therapy.(pharmaceutical indu..., April 25, 2005

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.